To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Primary Purpose
Leukopenia
Status
Unknown status
Phase
Early Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
GX-I7 or [14C] GX-I7
Sponsored by
About this trial
This is an interventional basic science trial for Leukopenia
Eligibility Criteria
Inclusion Criteria:
- Subject is willing and able to give informed consent after listening character of the clinical trial
- Must be 19-45 years of age, inclusive
- Weight 50-100kg, BMI 18-30kg/m2
- Subject who is adequately able to attend the study based on medical history and physical exam, no clinically significant abnormality from vital sign and clinical laboratory values
- No clinical abnormality from ECG test
- Non-smoker (no smoking or no use of any product containing nicotine least for one month and negative from urine test)
Exclusion Criteria:
- Suspected or confirmed malignancy, or has malignancy history
- Any clinically significant acute or chronic medical condition requiring care of a physician, in liver, biliary tract, renal, nervous system (CNS or peripheral). respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction etc), hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder, immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases
- Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab
- Are considering or scheduled to undergo any surgical or dental procedure during the study
- Administered other Investigational Product (IP) by attending other clinical study or biological equivalent study within recent 6 months
- Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical history with serious allergic diseases
- Positive from urine drug screen or respiratory alcohol screen at medical screening
- History of alcohol, drug, or substance abuse in the past 12 months
- A heavy alchol consumer (>21 units/week, 1 unit = 10 g of pure alcohol) or Consumption of alcohol within 48 hours prior to hospitalization
- Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or other hormone substitute within 14 days before administration
- Planning pregnancy or donation of sperm/disagreeing proper contraception during the study and 3 months following IP administration
- Do not have veins suitable for cannulation or multiple venipunctures
- Previously donate whole blood within 60 days or component blood within 14 days
- Excessive consumption of foods containing grapefruits
- Any other factor that the Investigator thinks will increase subject risk with participation
Sites / Locations
- Seoul National University Hospital Clinical Trial Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Part 1
Part 2
Part 3
Arm Description
IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
IV: [14C]-GX-I7 40 µg
IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
Outcomes
Primary Outcome Measures
Total radioactivity at feces,urine,blood to measure total recovery rate
radioactivity in nCi
Secondary Outcome Measures
Full Information
NCT ID
NCT04283695
First Posted
November 18, 2019
Last Updated
February 23, 2020
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04283695
Brief Title
To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Official Title
A Phase 1, Open-labeled, Single-dose, One-sequence, One-period, 3-part Study to Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 3, 2019 (Actual)
Primary Completion Date
August 30, 2019 (Actual)
Study Completion Date
May 1, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7 in healthy volunteers
Detailed Description
A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7 in healthy volunteers To show ABA and Mass balance of GX-I7
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukopenia
7. Study Design
Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Part 1
Arm Type
Experimental
Arm Description
IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
Arm Title
Part 2
Arm Type
Experimental
Arm Description
IV: [14C]-GX-I7 40 µg
Arm Title
Part 3
Arm Type
Experimental
Arm Description
IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
Intervention Type
Drug
Intervention Name(s)
GX-I7 or [14C] GX-I7
Intervention Description
IM GX-I7 or IV/IM microdose of GX-I7
Primary Outcome Measure Information:
Title
Total radioactivity at feces,urine,blood to measure total recovery rate
Description
radioactivity in nCi
Time Frame
29 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subject is willing and able to give informed consent after listening character of the clinical trial
Must be 19-45 years of age, inclusive
Weight 50-100kg, BMI 18-30kg/m2
Subject who is adequately able to attend the study based on medical history and physical exam, no clinically significant abnormality from vital sign and clinical laboratory values
No clinical abnormality from ECG test
Non-smoker (no smoking or no use of any product containing nicotine least for one month and negative from urine test)
Exclusion Criteria:
Suspected or confirmed malignancy, or has malignancy history
Any clinically significant acute or chronic medical condition requiring care of a physician, in liver, biliary tract, renal, nervous system (CNS or peripheral). respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction etc), hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder, immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases
Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab
Are considering or scheduled to undergo any surgical or dental procedure during the study
Administered other Investigational Product (IP) by attending other clinical study or biological equivalent study within recent 6 months
Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical history with serious allergic diseases
Positive from urine drug screen or respiratory alcohol screen at medical screening
History of alcohol, drug, or substance abuse in the past 12 months
A heavy alchol consumer (>21 units/week, 1 unit = 10 g of pure alcohol) or Consumption of alcohol within 48 hours prior to hospitalization
Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or other hormone substitute within 14 days before administration
Planning pregnancy or donation of sperm/disagreeing proper contraception during the study and 3 months following IP administration
Do not have veins suitable for cannulation or multiple venipunctures
Previously donate whole blood within 60 days or component blood within 14 days
Excessive consumption of foods containing grapefruits
Any other factor that the Investigator thinks will increase subject risk with participation
Facility Information:
Facility Name
Seoul National University Hospital Clinical Trial Center
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
We'll reach out to this number within 24 hrs